Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February

Grint, Daniel; Wing, Kevin; Williamson, Elizabeth; McDonald, Helen I; Bhaskaran, Krishnan; Evans, David; Evans, Stephen; Walker, Alex J; Hickman, George; Nightingale, Emily; Schultze, Anna; Rentsch, Christopher T; Bates, Chris; Cockburn, Jonathan; Curtis, Helen J; Morton, Caroline E; Bacon, Sebastian; Davy, Simon; Wong, Angel; Mehrkar, Amir; Tomlinson, Laurie; Douglas, Ian; Mathur, Rohini; Blomquist, Paula; MacKenna, Brian; Ingelsby, Peter; Croker, Richard; Parry, John; Hester, Frank; Harper, Sam; DeVito, Nicholas J; Hulme, William; Tazare, John; Smeeth, Liam; Eggo, Rosalind M

doi:10.2807/1560-7917.es.2021.26.11.2100256

Cited by 179 publications

(146 citation statements)

References 8 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“… 20 Previous studies have, however, not noted any association between B.1.1.7 status and body mass index or comorbidity in patients with covid-19. 8 9 Hence, we do not expect that these potential confounders were strongly associated with SGTF status. Furthermore, they were accounted for indirectly through age, sex, ethnicity, and deprivation.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis

Nyberg

Twohig

Harris

et al. 2021

BMJ

137

114

View full text Add to dashboard Cite

Objective To evaluate the relation between diagnosis of covid-19 with SARS-CoV-2 variant B.1.1.7 (also known as variant of concern 202012/01) and the risk of hospital admission compared with diagnosis with wild-type SARS-CoV-2 variants. Design Retrospective cohort analysis. Setting Community based SARS-CoV-2 testing in England, individually linked with hospital admission data. Participants 839 278 patients with laboratory confirmed covid-19, of whom 36 233 had been admitted to hospital within 14 days, tested between 23 November 2020 and 31 January 2021 and analysed at a laboratory with an available TaqPath assay that enables assessment of S-gene target failure (SGTF), a proxy test for the B.1.1.7 variant. Patient data were stratified by age, sex, ethnicity, deprivation, region of residence, and date of positive test. Main outcome measures Hospital admission between one and 14 days after the first positive SARS-CoV-2 test. Results 27 710 (4.7%) of 592 409 patients with SGTF variants and 8523 (3.5%) of 246 869 patients without SGTF variants had been admitted to hospital within one to 14 days. The stratum adjusted hazard ratio of hospital admission was 1.52 (95% confidence interval 1.47 to 1.57) for patients with covid-19 infected with SGTF variants, compared with those infected with non-SGTF variants. The effect was modified by age (P<0.001), with hazard ratios of 0.93-1.21 in patients younger than 20 years with versus without SGTF variants, 1.29 in those aged 20-29, and 1.45-1.65 in those aged ≥30 years. The adjusted absolute risk of hospital admission within 14 days was 4.7% (95% confidence interval 4.6% to 4.7%) for patients with SGTF variants and 3.5% (3.4% to 3.5%) for those with non-SGTF variants. Conclusions The results suggest that the risk of hospital admission is higher for people infected with the B.1.1.7 variant compared with wild-type SARS-CoV-2, likely reflecting a more severe disease. The higher severity may be specific to adults older than 30 years.

show abstract

Section: Discussionmentioning

confidence: 92%

“…2 4 5 On 18 December 2020, the variant was redesignated as a variant of concern (VOC-202012/01), and subsequent studies have found B.1.1.7 to be associated with higher mortality than other SARS-CoV-2 variants. 6 7 8 9 10…”

Section: Introductionmentioning

confidence: 99%

Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis

Nyberg

Twohig

Harris

et al. 2021

BMJ

137

114

View full text Add to dashboard Cite

show abstract

“…They share the N501Y mutation in RBD besides the D614G mutation around the S1/S2 cleavage site (Table 2, Figure 6). Epidemiological studies suggest that the UK variant correlates with higher viral loads in patients [306], a >40% increased epidemiological growth [307,308], a longer duration of acute infection [309], and increased severity/death rate, particularly in patients of higher age and with comorbidities [310][311][312][313]. The UK variant acquired an enhanced affinity to ACE2 [314] while maintaining sensitivity to nAb responses though with 2-9 times reduced nAb titers in vaccinees and convalescent individuals [314][315][316].…”

Section: Sars-cov-2 Mutates On a Low But Constant Level Yielding Mutant Variants Over Timementioning

confidence: 99%

SARS-CoV-2 Portrayed Against HIV: Contrary Viral Strategies in Similar Disguise

Duerr¹,

Jimenez²,

Dittmann³

2021

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 and HIV are zoonotic viruses that rapidly reached pandemic scale causing global losses and fear. The COVID-19 and AIDS pandemics ignited massive efforts worldwide to develop antiviral strategies and characterize viral architectures, biological and immunological properties, and clinical outcomes. Although both viruses have a comparable appearance as enveloped, positive-stranded RNA viruses with envelope spikes mediating cellular entry, the entry process, downstream biological and immunological pathways, clinical outcomes, and disease courses are strikingly different. This review provides a systemic comparison of both viruses’ structural and functional characteristics delineating their distinct strategies for efficient spread.

show abstract

“…Variant B.1.1.7 was first reported in the UK on September 2020 and by December 2020 became the dominant strain in the country (2). Its increased infectivity led to its rapid spread, with severe consequences on public health and global economy (4). Likewise, from its first detection in Israel on December 23, this variant now comprises over 90% of the positive cases (O. Erster and N. Zuckerman, Unpublished data).…”

Section: Introductionmentioning

confidence: 99%

Rapid And high throughput RT-qPCR assay for identification and differentiation between SARS-CoV-2 variants B.1.1.7 and B.1.351

Erster

Mendelson

Levy

et al. 2021

Preprint

View full text Add to dashboard Cite

Emerging SARS-CoV-2 (SC-2) variants with increased infectivity and vaccine resistance are of major concern. Rapid identification of such variants is important for the public health activities and provide valuable data for epidemiological and policy decision making. We developed a multiplex quantitative RT-qPCR (qPCR) assay that can specifically identify and differentiate between the emerging B.1.1.7 and B.1.351 SC-2 variants. In a single assay, we combined four reactions: one that detects SC-2 RNA independently of the strain, one that detects the D3L mutation, which is specific to variant B.1.1.7, and one that detects the 242-244 deletion, which is specific to variant B.1.351. The fourth reaction identifies human RNAseP gene, serving as an endogenous control for RNA extraction integrity. We show that the strain-specific reactions target mutations that are strongly associated with the target variants, and not with other major known variants. The assay specificity was tested against a panel of respiratory pathogens (n=16), showing high specificity towards SC-2 RNA. The assay sensitivity was assessed using both In-vitro transcribed RNA and clinical samples, and was determined to be between 20 and 40 viral RNA copies per reaction. The assay performance was corroborated with Sanger and whole genome sequencing, showing complete agreement with the sequencing results. The new assay is currently implemented in the routine diagnostic work at the Central Virology Laboratory, and may be used in other laboratories to facilitate the diagnosis of these major worldwide circulating SC-2 variants.

show abstract

Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February

Cited by 179 publications

References 8 publications

Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis

Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis

SARS-CoV-2 Portrayed Against HIV: Contrary Viral Strategies in Similar Disguise

Rapid And high throughput RT-qPCR assay for identification and differentiation between SARS-CoV-2 variants B.1.1.7 and B.1.351

Contact Info

Product

Resources

About